Aditi Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aditi Jain has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Abdelaziz
St. Elizabeth Medical Center, Boston, MA 02135, USA
2 shared publications - Geeta Joshi
Department of Medical Education, UTHealth San Antonio, San Antonio, TX 78229, USA
2 shared publications - Harshit Garg
Department of Urology, University of Texas Health, San Antonio, TX
2 shared publications - Mukund Bhandari
Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas
2 shared publications - Pushkar Joshi
Department of Management, Webster University, San Antonio, TX 78213, USA
2 shared publications - Shalini Reddy Araveeti
New England College, Henniker, NH 03242, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 7 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2519
The Current Landscape of Clinical Trials
Background/Objectives: Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. Methods: This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining the current landscape, challenges, and innovations that have shaped the field over the past century. Data were extracted on 7 March 2025 and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. Results: The analysis reveals a continuous increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. Conclusions: The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- 7 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2519
Top Cited PapersOpen AccessThe Current Landscape of Clinical Trials
Background/Objectives: Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. Methods: This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining the current landscape, challenges, and innovations that have shaped the field over the past century. Data were extracted on 7 March 2025 and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. Results: The analysis reveals a continuous increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. Conclusions: The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- Open Access
- 26 December 2024
- Published by Scientific Scholar in Fertility Science & Research
- Vol. 11, 17
Categorisation of Adnexal Masses in Infertile Women: A Retrospective Cohort Analysis
Objectives: Adnexal lesions are often detected incidentally during infertility evaluation. However, limited data exists on the pathological profile of adnexal lesions detected, particularly in infertile women. In this study, we aim to assess the histopathological profile of adnexal masses in infertile women. Material and Methods: Retrospective analysis of infertile women with an adnexal mass undergoing surgery between 1 January 2018 and 30 May 2024 was done. Details pertaining to demographic profile, ultrasonography, biochemical markers, surgical findings and histopathology were retrieved. Histopathological profile was studied as per the Royal College of Obstetricians and Gynaecology (RCOG) histopathological classification. Statistical analysis was done using the SPSS Statistics software (v27.0). Results: Of the 5170 patients screened, 62 patients eligible for study criteria were included. The mean age (standard deviation [SD]) was 33.1 (4.6) years, with 85.5% (53/62) of patients being nulliparous. Ultrasonographic evaluation revealed bilateral adnexal lesions in 25.8% (16/62) patients. Most patients underwent laparoscopic surgery (91.9%, 57/62). CA-125 was available for 34 patients and was raised in 58.9% (20/34) patients. The histopathological profile revealed 93.6% (58/62) of patients having benign lesions of ovarian origin, while 3.2% (2/62) had benign lesions of non-ovarian origin. Endometriosis (66.1%, 41/62) and mature teratoma (12.9%, 8/62) were the most common benign lesions. Two patients (3.2%) with malignancy had borderline mucinous tumours. Conclusion: Benign ovarian lesions form the most common adnexal masses in women of reproductive age group who present with infertility; however, malignancy is not uncommon. Endometriosis and mature teratoma appeared to be the most common benign lesions.
- 26 December 2024
- Published by Scientific Scholar in Fertility Science & Research
- Vol. 11, 17
Open AccessCategorisation of Adnexal Masses in Infertile Women: A Retrospective Cohort Analysis
Objectives: Adnexal lesions are often detected incidentally during infertility evaluation. However, limited data exists on the pathological profile of adnexal lesions detected, particularly in infertile women. In this study, we aim to assess the histopathological profile of adnexal masses in infertile women. Material and Methods: Retrospective analysis of infertile women with an adnexal mass undergoing surgery between 1 January 2018 and 30 May 2024 was done. Details pertaining to demographic profile, ultrasonography, biochemical markers, surgical findings and histopathology were retrieved. Histopathological profile was studied as per the Royal College of Obstetricians and Gynaecology (RCOG) histopathological classification. Statistical analysis was done using the SPSS Statistics software (v27.0). Results: Of the 5170 patients screened, 62 patients eligible for study criteria were included. The mean age (standard deviation [SD]) was 33.1 (4.6) years, with 85.5% (53/62) of patients being nulliparous. Ultrasonographic evaluation revealed bilateral adnexal lesions in 25.8% (16/62) patients. Most patients underwent laparoscopic surgery (91.9%, 57/62). CA-125 was available for 34 patients and was raised in 58.9% (20/34) patients. The histopathological profile revealed 93.6% (58/62) of patients having benign lesions of ovarian origin, while 3.2% (2/62) had benign lesions of non-ovarian origin. Endometriosis (66.1%, 41/62) and mature teratoma (12.9%, 8/62) were the most common benign lesions. Two patients (3.2%) with malignancy had borderline mucinous tumours. Conclusion: Benign ovarian lesions form the most common adnexal masses in women of reproductive age group who present with infertility; however, malignancy is not uncommon. Endometriosis and mature teratoma appeared to be the most common benign lesions.
- Open Access
- 6 September 2024
- Published by MDPI AG in Preprints.org
The Current Landscape of Clinical Trials
Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining trends, challenges, and innovations that have shaped the field over the past century. Data were extracted on July 15, 2024, and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. The analysis reveals a significant increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, and are predominantly interventional, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.
- 6 September 2024
- Published by MDPI AG in Preprints.org
Open AccessThe Current Landscape of Clinical Trials
Clinical trials are essential in the development of new medical treatments, offering crucial data on their safety and effectiveness. This study provides a comprehensive analysis of clinical trials registered on ClinicalTrials.gov, examining trends, challenges, and innovations that have shaped the field over the past century. Data were extracted on July 15, 2024, and analyzed to identify patterns in trial design, sponsorship, participant demographics, and geographical distribution. The analysis reveals a significant increase in clinical trial registrations, peaking in 2021, driven by the COVID-19 pandemic. Most trials focus on cancer, reflecting its global burden, and are predominantly interventional, with randomized controlled trials (RCTs) being the most common study design. However, challenges persist, including underrepresentation of certain demographics, limited global distribution, and insufficient reporting of trial results. Additionally, the underrepresentation of pediatric, elderly, and minority populations in trials limits the generalizability of findings. The analysis underscores the need for more inclusive and globally distributed research to address disparities in health outcomes.